GranuFlo Lawyers Investigating Claims of Sudden Cardiac Events In Dialysis Patients

(, August 19, 2013 ) New York, NY – The attorneys working with are investigating potential lawsuits on behalf of patients who suffered a sudden cardiac event after undergoing dialysis with GranuFlo or NaturaLyte.

If you or a loved one suffered from a heart attack or other adverse cardiac event during or shortly after dialysis, you may be entitled to financial compensation. To learn more about your potential legal rights and to receive a free, no obligation case review, please visit

Numerous lawsuits have been filed across the country alleging that GranuFlo and NaturaLyte were unreasonably dangerous. The lawsuits contend that these dialysis products can cause heart attacks, cardiac arrest, sudden cardiac death, and other adverse medical conditions. According to court documents, plaintiffs allege that GranuFlo and NaturaLyte are associated with a rapid and unsafe elevation of bicarbonate, which has been linked to an increased risk of cardiopulmonary arrest and death.

The lawsuits allege that Fresenius Medical Care, the manufacturer of GranuFlo and NaturaLyte, failed to fully inform patients and health care providers of the dangerous side effects associated with its dialysis products. Specifically, lawsuits have asserted that the labeling on the products did not provide adequate warnings of severe and disabling medical conditions, such as cardiac arrest and other dangerous medical conditions. Plaintiffs in the lawsuits allege that as early as January of 2010, Fresenius had analyzed data and found that 941 patients from 667 facilities had cardiopulmonary arrests, six times as many as that of competing products and failed to alert the medical community of these risks.

As reported in the New York Times, in November of 2011 Fresenius Medical Care issued an internal memo to company doctors stating that the failure to properly use GranuFlo and NaturaLyte appeared to be contributing to a sharp increase in the risk of patients dying suddenly from cardiac arrest. Fresenius, however, did not immediately warn other dialysis centers of the risks associated with GranuFlo and NaturaLyte. According to the New York Times, Fresenius only began warning other dialysis centers about the dangers of GranuFlo and NaturaLyte after the internal memo was anonymously leaked to the U.S. Food and Drug Administration. In March of 2012, the FDA issued a recall for Granuflo and NaturaLyte and advised the public that these products may cause serious adverse health consequences, including death.

As the GranuFlo and NaturaLyte lawsuits move forward, our attorneys continue to investigate potential claims on behalf of patients who may have suffered adverse health effects because of these allegedly unsafe dialysis products. If you or a loved one has suffered a sudden cardiac event during or shortly after dialysis, please visit for a free evaluation of your claim.

About Class

Class is dedicated to protecting consumers and investors in class actions and complex litigation throughout the United States. Class keeps consumers informed about product alerts, recalls, and emerging litigation and helps them take action against the manufacturers of defective products, drugs, and medical devices. Information about consumer fraud issues and environmental hazards is also available on the site. Visit today for a no cost, no obligation case evaluation and information about your consumer rights.
Whitney Shields

Source: EmailWire.Com
Subscribe to LegalLaw247.Com Newsletter

Leave a Reply

Your email address will not be published. Required fields are marked *



You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>